Nirsevimab (Beyfortus) 50 mg Open for Ordering for a Limited Time

Posted on October 08, 2024

Date: October 7, 2024

The Maine Immunization Program is pleased to announce that nirsevimab (Beyfortus) 50 mg for infants is now open to order for a limited time through ImmPact to all enrolled Vaccines for Children (VFC) providers. Allocation is available to order from Monday, October 7, 2024, to close of business on Friday, October 11, 2024, or until all available inventory has been ordered.

Ordering is available at a minimum quantity of 5 doses and a maximum quantity of 10 doses per site. Due to allocation constraints, enrolled provider sites will not be able to order their full season supply at this time.

Nirsevimab 100 mg doses remains available to all enrolled VFC providers for order at a minimum quantity of 5 doses and maximum quantity of 100 doses per order.

**All orders MUST be placed separate from regular vaccine orders. Orders placed with other vaccines in ImmPact will be denied.

All remaining nirsevimab products in the State of Maine from the 2023-2024 season have an expiration date ending in 2025. Any remaining inventory from last season should continue to be stored at appropriate temperature and used first at the start of the 2024-2025 RSV season.

Nirsevimab (Beyfortus) Immunization Recommendations:

  • Infants (Under 8 Months): All infants entering their first RSV season should receive a single dose of nirsevimab unless their mother received an RSV vaccine during pregnancy.
  • 50 mg for infants weighing <5 kg [<11 lb]
  • 100 mg for infants weighing ≥5 kg [≥11 lb]
  • Children (8-19 Month): High-risk children, including those with chronic lung disease of prematurity who required medical support any time during the 6-month period before the start of the second RSV season or with severe immunocompromise, should receive 200 mg for their second RSV season.

Nirsevimab Storage:

  • Store syringes between 36°F to 46°F and use them within 8 hours if stored at room temperature. Discard if not used in time.

Administration with Other Vaccines:

  • Nirsevimab can be given alongside routine vaccines, including live vaccines like MMR and Varicella.

Documentation in ImmPact:

  • Providers must document administered doses in ImmPact within 5 business days.
  • ImmPact will not forecast nirsevimab immunizations, due to the complexity of the ACIP recommended schedule. 

For any questions, please contact the Maine Immunization Program at (207) 287-3746 or email ImmunizeME.DHHS@maine.gov